Anavex Life Sciences Corp (AVXL)

[LBSR TO DA MOON]

FWIW regarding potential value of Priority Review Vouchers:

Bluebird Bio Agrees to Sell Priority Review Voucher for $103 million, if Sickle Cell Disease Treatment Approved
MT NEWSWIRES 11:33 AM ET 10/30/2023
11:33 AM EDT, 10/30/2023 (MT Newswires) -- Bluebird bio (BLUE) said Monday it agreed to sell Rare Pediatric Disease Priority Review Voucher, or PRV, if received, in relation to the potential approval of lovotibeglogene autotemcel for the treatment of sickle cell disease.
The PRV program encourages creating medicines for rare kids' diseases, the company said.
Under the terms of the deal, the buyer will acquire PRV rights, and the company will receive $103 million upon the sale's completion, subject to US Food and Drug Administration's approval of the biologics license application for lovotibeglogene autotemcel and PRV issuance, the company added.
Price: 2.77, Change: +0.04, Percent Change: +1.47
MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.